Therapeutic Response

BCR::ABL1 status confers therapeutic sensitivity to Bosutinib in patients with Chronic Myeloid Leukemia, BCR-ABL1+.

Statements

Source and description
Bosulif (bosutinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult and pediatric patients 1 year of age and older with chronic phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), newly-diagnosed or resistant or intolerant to prior therapy.
Bosulif (bosutinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to bosutinib for the treatment of adult patients with accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.
Bosulif (bosutinib) [product monograph]. HC. Health Canada approved bosutinib for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML).
Bosulif (bosutinib) [product monograph]. HC. Health Canada approved bosutinib for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy.